Company Overview: AXSM

Upcoming Projects (AXSM)

Evaluating the Phase 3 Clinical Results of AXS-05 for Alzheimer’s Disease Agitation from Axsome Therapeutics
Ticker: AXSM
Execute By: Jul 31, 2025
Analyzing the PARADIGM Phase 3 Trial Results of Solriamfetol in Major Depressive Disorder with and without Excessive Daytime Sleepiness from Axsome Therapeutics
Ticker: AXSM
Execute By: Jul 31, 2025

Executed Projects (AXSM)

Quarterly Survey: Depression Bipolar Disorder Treatments & AXSM's Auvelity and ITCI's Caplyta April 2025
Tickers: AXSM, ITCI, TAK
Executed On: Apr 25, 2025 at 11:31 AM EDT
Quarterly Survey: Depression Bipolar Disorder Treatments & AXSM's Auvelity and ITCI's Caplyta January 2025
Tickers: AXSM, ITCI, TAK
Executed On: Jan 28, 2025 at 11:00 AM EST
A look at Axsome's AXS-12 (reboxetine) and the data from Phase 3 ENCORE trial in patients with narcolepsy with cataplexy.
Ticker: AXSM
Executed On: Jan 08, 2025 at 09:30 AM EST
Quarterly Survey: Depression Bipolar Disorder Treatments & AXSM's Auvelity and ITCI's Caplyta October 2024
Tickers: AXSM, ITCI, TAK
Executed On: Oct 18, 2024 at 03:03 PM EDT
Quarterly Survey: Depression Bipolar Disorder Treatments & AXSM's Auvelity and ITCI's Caplyta July 2024
Tickers: AXSM, ITCI, TAK
Executed On: Jul 31, 2024 at 01:02 PM EDT
Quarterly Survey: Depression Bipolar Disorder Treatments and AXSM's Auvelity and ITCI's Caplyta April 2024
Tickers: AXSM, ITCI, TAK
Executed On: Apr 18, 2024 at 12:59 PM EDT
Discussing the Phase 3 trial results of Axsome Therapeutics AXS-12 for patients with narcolepsy
Ticker: AXSM
Executed On: Apr 11, 2024 at 09:00 AM EDT
Quarterly Survey: Depression Bipolar Disorder Treatments and AXSM's Auvelity and ITCI's Caplyta January 2024
Tickers: AXSM, ITCI, TAK
Executed On: Jan 19, 2024 at 02:45 PM EST
Quarterly Survey: Depression Bipolar Disorder Treatments and AXSM's Auvelity and ITCI's Caplyta October 2023
Tickers: AXSM, ITCI, TAK
Executed On: Nov 03, 2023 at 01:07 PM EDT
Discussing therapeutic options for Narcolepsy Type 1 and investigational agents
Tickers: JAZZ, AXSM, HRMY, TAK, AVDL
Executed On: Aug 14, 2023 at 12:00 PM EDT
Quarterly Survey: Depression and Auvelity and Caplyta July 2023
Tickers: AXSM, ITCI
Executed On: Jul 28, 2023 at 03:17 PM EDT
Quarterly Survey: Depression Bipolar Disorders and Auvelity and Caplyta April 2023
Tickers: AXSM, ITCI
Executed On: Apr 14, 2023 at 03:36 PM EDT
Quarterly Survey: Depression Bipolar Disorders and Auvelity and Caplyta
Tickers: ITCI, AXSM
Executed On: Feb 07, 2023 at 04:47 PM EST
A Second View: Digging into the recent data from the ACCORD Phase 3 Trial of Axsome's AXS-05 in Alzheimer’s Disease Agitation
Ticker: AXSM
Executed On: Dec 21, 2022 at 04:00 PM EST
A Second View: Checking in with a prescriber of Axsome's SUNOSI (Solriamfetol) in treating excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea (OSA)
Ticker: AXSM
Executed On: Dec 09, 2022 at 11:00 AM EST
Digging into the recent data from the ACCORD Phase 3 Trial of Axsome's AXS-05 in Alzheimer’s Disease Agitation
Ticker: AXSM
Executed On: Dec 07, 2022 at 01:15 PM EST
Two Week Delay: Survey on Auvelity's potential in MDD, including what therapies in development are most exciting for treating patients.
Ticker: AXSM
Executed On: Dec 01, 2022 at 10:58 AM EST
Checking in with a prescriber of Axsome's SUNOSI (Solriamfetol) in treating excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea (OSA)
Ticker: AXSM
Executed On: Nov 29, 2022 at 11:00 AM EST
Examining the use of Nurtech in migraines and where AXS-07 could fit in if approved
Tickers: AXSM, BHVN, PFE
Executed On: Jul 22, 2022 at 11:00 AM EDT
Looking at the potential of REL-1017 in treating Depression ahead of multiple Phase 3 readouts in 2022.
Tickers: RLMD, AXSM, SAGE, BTAI, XENE
Executed On: Apr 07, 2022 at 03:30 PM EDT
Digging into Axsome's AXS-07 for the acute treatment of migraine
Ticker: AXSM
Executed On: Mar 18, 2022 at 04:45 PM EDT

Upcoming & Overdue Catalysts (AXSM)

Don’t see a catalyst related to the company you care about? Create your own!

Occurred Catalysts (AXSM)

FDA points to deficiencies within Axsome's (AXSM) AXS-05 regulatory application. Final decision on AXS-05's regulatory review for Major Depressive Disorder postponed for Aug. 22, 2021
Ticker: AXSM
Occurred on: Aug 23, 2021
Axsome Therapeutics (AXSM) Presents New Data from MOMENTUM Phase 3 Trial with AXS-07 in the Acute Treatment of Migraine
Ticker: AXSM
Occurred on: Sep 24, 2020
Axsome's (AXSM) AXS-05 Data Results from GEMINI Phase 3 Trial in Major Depressive Disorder
Ticker: AXSM
Occurred on: Dec 16, 2019
Phase 3 trial of AXS-02 for Complex regional pain syndrome (CRPS) expected to be completed by end of 2017 - Discontinued
Ticker: AXSM
Occurred on: Jan 09, 2018
AXS-02 Independent Data Monitoring Committee Recommends Continuation of COAST-1 Trial and Discontinuation of CREATE-1 Trial
Ticker: AXSM
Occurred on: Jan 09, 2018
Axsome Therapeutics Initiates Phase 3 Study of AXS-05 for Treatment Resistant Depression
Ticker: AXSM
Occurred on: Mar 17, 2016
Axsome Therapeutics Receives New U.S. Patent Covering AXS-02 for the Treatment of Complex Regional Pain Syndrome; Provides Patent Protection for AXS-02 into 2033 and Covers Uses of Oral Zoledronic Acid for Complex Regional Pain Syndrome
Ticker: AXSM
Occurred on: Mar 15, 2016
Axsome Therapeutics Announces Issuance of U.S. Patent Covering AXS-02 for the Treatment of Bone Marrow Lesions of the Knee; Provides Patent Protection into 2033
Ticker: AXSM
Occurred on: Jan 27, 2016

Strategic Initiatives (AXSM)

Don’t see a strategic initiative related to the company you care about? Create your own!

AXSM Overview